大肠癌辅助化疗综述

Shahireen Shahireen, Vipplavi Eka, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L
{"title":"大肠癌辅助化疗综述","authors":"Shahireen Shahireen, Vipplavi Eka, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L","doi":"10.26452/fjphs.v4i1.567","DOIUrl":null,"url":null,"abstract":"Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer globally. For loco regional colon cancer, surgery is the sole curative option. Adjuvant chemotherapy aims to eliminate micro metastases and increase survival. It has been most convincingly proven in stage III illness, even though there is ongoing debate on the usefulness of adjuvant chemotherapy for stage II illness. For the past fifteen years, six months of adjuvant chemotherapy with an oxaliplatin-based chemotherapy has been the accepted standard of care for stage III colon cancer. It is still advised to use 6 months of adjuvant chemotherapy for individuals with stage II illness and high clinicopathological risk. Chemo radiation therapy (CRT) is frequently used as neoadjuvant or adjuvant therapy in the treatment of stage II and stage III rectal cancers because this cancer type has a higher risk of local recurrence than other cancer types.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"60 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An expatiate review on adjuvant chemotherapy of colorectal cancer\",\"authors\":\"Shahireen Shahireen, Vipplavi Eka, Kavya Rachamsetty, Dhachinamoorthi Duraiswamy, Rama Chandra Reddy L\",\"doi\":\"10.26452/fjphs.v4i1.567\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer globally. For loco regional colon cancer, surgery is the sole curative option. Adjuvant chemotherapy aims to eliminate micro metastases and increase survival. It has been most convincingly proven in stage III illness, even though there is ongoing debate on the usefulness of adjuvant chemotherapy for stage II illness. For the past fifteen years, six months of adjuvant chemotherapy with an oxaliplatin-based chemotherapy has been the accepted standard of care for stage III colon cancer. It is still advised to use 6 months of adjuvant chemotherapy for individuals with stage II illness and high clinicopathological risk. Chemo radiation therapy (CRT) is frequently used as neoadjuvant or adjuvant therapy in the treatment of stage II and stage III rectal cancers because this cancer type has a higher risk of local recurrence than other cancer types.\",\"PeriodicalId\":12614,\"journal\":{\"name\":\"Future Journal of Pharmaceuticals and Health Sciences\",\"volume\":\"60 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceuticals and Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26452/fjphs.v4i1.567\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceuticals and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26452/fjphs.v4i1.567","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

结肠直肠癌是导致癌症相关死亡的第二大原因,也是全球第三大常见癌症。对于局部区域性结肠癌,手术是唯一的根治选择。辅助化疗旨在消除微小转移灶,提高生存率。尽管关于辅助化疗对 II 期癌症是否有用的争论仍在继续,但辅助化疗在 III 期癌症中的疗效已得到最令人信服的证实。在过去的 15 年中,以奥沙利铂为基础的 6 个月辅助化疗一直是公认的 III 期结肠癌治疗标准。对于病情处于 II 期且临床病理风险较高的患者,仍建议使用 6 个月的辅助化疗。化疗放疗(CRT)经常作为新辅助或辅助疗法用于 II 期和 III 期直肠癌的治疗,因为这种癌症类型的局部复发风险高于其他癌症类型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
An expatiate review on adjuvant chemotherapy of colorectal cancer
Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer globally. For loco regional colon cancer, surgery is the sole curative option. Adjuvant chemotherapy aims to eliminate micro metastases and increase survival. It has been most convincingly proven in stage III illness, even though there is ongoing debate on the usefulness of adjuvant chemotherapy for stage II illness. For the past fifteen years, six months of adjuvant chemotherapy with an oxaliplatin-based chemotherapy has been the accepted standard of care for stage III colon cancer. It is still advised to use 6 months of adjuvant chemotherapy for individuals with stage II illness and high clinicopathological risk. Chemo radiation therapy (CRT) is frequently used as neoadjuvant or adjuvant therapy in the treatment of stage II and stage III rectal cancers because this cancer type has a higher risk of local recurrence than other cancer types.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Design and characterization of controlled release formulation of Mesna by using different polymers Deciphering the role and impact of India's pharmaceutical industries and its regulatory compliance Formulation and evaluation of Metoprolol succinate buccal tablets in hypertension treatment Formulation and evaluation of amoxapine mucoadhesive buccal films Significance of Alternative Medicines in Treatment of Chronic Diseases: A Comprehensive Review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1